Anti-CCR5 Agents Block Cancer Metastasis, CytoDyn
Summary
The EPO published patent application EP3947431A1 filed by CytoDyn Inc. on April 15, 2026, titled Anti-CCR5 Agents and Methods of Treatment That Block Cancer Metastasis or Enhance Cell Death Induced by DNA Damaging Chemotherapy. The application lists inventors Richard G. Pestell and Scott Kelly and covers anti-CCR5 agents for blocking cancer metastasis or enhancing cell death from DNA-damaging chemotherapy. The designation covers 35 European Patent Convention member states, potentially providing CytoDyn with patent protection across those jurisdictions upon grant.
About this source
GovPing monitors EPO Patent Bulletin - Peptides (C07K) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 22 changes logged to date.
What changed
The EPO published patent application EP3947431A1 for CytoDyn Inc. covering anti-CCR5 agents and methods of treatment for blocking cancer metastasis or enhancing cell death induced by DNA-damaging chemotherapy. The application names Richard G. Pestell and Scott Kelly as inventors and is classified under IPC codes C07K 14/705, C07K 14/725, and C07K 16/10. Designated states include all 35 EPC contracting states across the EU and broader Europe.
Entities monitoring cancer treatment R&D or considering licensing anti-CCR5 therapies should review this publication for potential blocking positions. The patent application does not yet grant rights; protection will only attach upon grant following EPO examination.
Archived snapshot
Apr 22, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
ANTI-CCR5 AGENTS AND METHODS OF TREATMENT THAT BLOCK CANCER METASTASIS OR ENHANCE CELL DEATH INDUCED BY DNA DAMAGING CHEMOTHERAPY
Publication EP3947431A1 Kind: A1 Apr 15, 2026
Applicants
CytoDyn Inc.
Inventors
PESTELL, Richard, G., KELLY, Scott
IPC Classifications
C07K 14/705 20060101AFI20221121BHEP C07K 14/725 20060101ALI20221121BHEP C07K 16/10 20060101ALI20221121BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Parties
Related changes
Get daily alerts for EPO Patent Bulletin - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.